Molecular monitoring of treatment response in patients with chronic myelogenous leukemia is performed using the Europe Against Cancer (EAC) qPCR assay using the International Scale (IS). The assay amplifies both e13a2 and e14a2 BCR-ABL1 transcript variants. Observing distinct variant-dependent amplification curves during qPCR, the authors aimed to determine if this affected quantitation of BCR-ABL1. Their findings suggest that the EAC qPCR assay may underestimate the e14a2 variant compared to the e13a2 variant.

Read the article